Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer

Abstract

BACKGROUND: Cisplatin-based chemoradiation (CRT) is the standard treatment for patients with locally advanced cervical cancer. Epidermal growth factor receptor (EGFR) is frequently overexpressed in cervical cancer, and EGFR inhibition itself has antitumor effects and potentiates CRT. Results of a previous phase 1 trial of the EGFR inhibitor erlotinib combined with cisplatin-based CRT (E 1 CRT) recommended a phase 2 erlotinib dose of 150 mg/day. METHODS: Eligibility criteria included International Federation of Gynecology and Obstetrics stage IIB to IIIB epidermoid cervical cancer, no prior therapy, and an Eastern Cooperative Oncology Group performance status of 0 to 2. Patients received erlotinib at a dose of 150 mg/day 1 week before and in combination with cisplatin (40 mg/m 2 administered weekly for 5 cycles) and radiotherapy (4500 centigrays in 25 fractions), followed by brachytherapy (4 fractions at a dose of 600 centigrays weekly). RESULTS: A total of 36 patients completed treatment with E 1 CRT. The median duration of therapy was 77 days and the median follow-up period was 59.3 months. The therapy was well tolerated overall, and 34 patients (94.4%) achieved a complete response. The 2-year and 3-year cumulative overall and progression-free survival rates were 91.7% and 80.6% and 80% and 73.8%, respectively. CONCLUSIONS: Treatment with E 1 CRT appears to be safe and exerts significant activity against locally advanced cervical cancer. To the best of the authors' knowledge, this is the first study to date to demonstrate that a target agent has promising activity against locally advanced cervical cancer. Cancer 2014;120:1187-93.

Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer

“…Cervical cancer is the third most common cancer among women and the third leading cause of death26. The standard treatment for cervical cancer is cisplatin-based chemotherapy after surgery, which usually yields positive results in initial treatment27. In many cases, however, chemoresistance is induced by prolonged cisplatin-based treatment, which has significant toxicity28.…”

Neoadjuvant Chemotherapy Followed by Chemoradiation in Cervical Carcinoma: A Review

“…Few reports may consistently add information about alternative and additional approaches over this standard. 8,21 Neoadjuvant chemotherapy is effective in cervical cancer patients' treatment. The published trial RR observed with NATC varies from 67% to 69% comparing with less than 30% in the metastatic disease.…”

Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review

“…Although the systemic treatment of cervical squamous cell carcinoma (CSCC) has advanced into an era of targeted drugs, such as erlotinib (3) and bevacizumab (4), the antitumor efficacies of current therapies are limited, most likely due to the high degree of cancer clonal heterogeneity, intratumoral genetic heterogeneity and cell signal complexity (5). In this context, there is an urgent necessity for more active treatment and rationally designed targeted therapies (6).…”